Cargando…

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma

BACKGROUND: Melphalan is one of the most active chemotherapeutic agents in the treatment of multiple myeloma (MM). However, the mechanism underlying differential patient responses to melphalan therapy is unknown. METHODS: Chromatin structure, transcriptional activity and DNA damage response signals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gkotzamanidou, M, Sfikakis, P P, Kyrtopoulos, S A, Bamia, C, Dimopoulos, M A, Souliotis, V L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183844/ https://www.ncbi.nlm.nih.gov/pubmed/25051404 http://dx.doi.org/10.1038/bjc.2014.410

Ejemplares similares

Correction: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma
por: Gkotzamanidou, M., et al.
Publicado: (2020)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus
por: Souliotis, Vassilis L., et al.
Publicado: (2016)

Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2015)

Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy
por: Gkotzamanidou, Maria, et al.
Publicado: (2021)

Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk
por: Waller, Rosalie G., et al.
Publicado: (2018)

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
por: Melea, Pelagia I., et al.
Publicado: (2014)

The DNA damage response network in the treatment of head and neck squamous cell carcinoma
por: Psyrri, A., et al.
Publicado: (2021)

The role of epigenetics in the biology of multiple myeloma
por: Dimopoulos, K, et al.
Publicado: (2014)

Global genome nucleotide excision repair is organized into domains that promote efficient DNA repair in chromatin
por: Yu, Shirong, et al.
Publicado: (2016)

Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects.
por: Kyrtopoulos, S A, et al.
Publicado: (1993)

Transcription factor-pathway co-expression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma
por: Wang, Xujun, et al.
Publicado: (2013)

Metabolic Disorders in Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
por: Bamias, A, et al.
Publicado: (2013)

Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma
por: Ferro, Daniela P., et al.
Publicado: (2011)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
por: Patnaik, A, et al.
Publicado: (2014)

Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol
por: Heinrich, M., et al.
Publicado: (2016)

Transcriptional Stress Induces Chromatin Relocation of the Nucleotide Excision Repair Factor XPG
por: Scalera, Claudia, et al.
Publicado: (2021)

VAD chemotherapy as remission induction for multiple myeloma.
por: Anderson, H., et al.
Publicado: (1995)

Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment
por: Sfiridaki, K., et al.
Publicado: (2011)

Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma
por: Chakraborty, Chandraditya, et al.
Publicado: (2022)

Requirement for PBAF in Transcriptional Repression and Repair at DNA Breaks in Actively Transcribed Regions of Chromatin
por: Kakarougkas, Andreas, et al.
Publicado: (2014)

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2011)

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
por: Brugnatelli, S., et al.
Publicado: (1996)

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
por: Johnstone, Megan, et al.
Publicado: (2022)

At the intersection of non-coding transcription, DNA repair, chromatin structure, and cellular senescence
por: Ohsawa, Ryosuke, et al.
Publicado: (2013)

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma
por: Ordoñez, Raquel, et al.
Publicado: (2020)

Chromatin remodeling by Pol II primes efficient Pol III transcription
por: Yague-Sanz, Carlo, et al.
Publicado: (2023)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

DNA Damage Response and Oxidative Stress in Systemic Autoimmunity
por: Souliotis, Vassilis L., et al.
Publicado: (2019)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

The great repression: Chromatin and cryptic transcription
por: Hennig, Bianca P., et al.
Publicado: (2013)

Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma
por: Alvarez-Benayas, Jaime, et al.
Publicado: (2021)

Detection of Benzo[a]pyrene Diol Epoxide Adducts to Histidine and Lysine in Serum Albumin In Vivo by High-Resolution-Tandem Mass Spectrometry
por: Zurita, Javier, et al.
Publicado: (2022)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bke1e13hum2qrssc55tut6gc2i